BR0306685A - Composição farmacêutica contendo grelina - Google Patents
Composição farmacêutica contendo grelinaInfo
- Publication number
- BR0306685A BR0306685A BR0306685-1A BR0306685A BR0306685A BR 0306685 A BR0306685 A BR 0306685A BR 0306685 A BR0306685 A BR 0306685A BR 0306685 A BR0306685 A BR 0306685A
- Authority
- BR
- Brazil
- Prior art keywords
- buffer
- pharmaceutical composition
- ghrelin
- phosphate
- composition containing
- Prior art date
Links
- 101800001586 Ghrelin Proteins 0.000 title abstract 4
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 102000012004 Ghrelin Human genes 0.000 title 1
- 102100033367 Appetite-regulating hormone Human genes 0.000 abstract 5
- 239000000872 buffer Substances 0.000 abstract 5
- 101710111255 Appetite-regulating hormone Proteins 0.000 abstract 2
- 102000000393 Ghrelin Receptors Human genes 0.000 abstract 2
- 108010016122 Ghrelin Receptors Proteins 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 2
- 239000003324 growth hormone secretagogue Substances 0.000 abstract 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 abstract 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 abstract 1
- 239000008351 acetate buffer Substances 0.000 abstract 1
- PFTCBBOADJQVTP-UHFFFAOYSA-N acetic acid;boric acid;phosphoric acid Chemical compound CC(O)=O.OB(O)O.OP(O)(O)=O PFTCBBOADJQVTP-UHFFFAOYSA-N 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 239000007979 citrate buffer Substances 0.000 abstract 1
- 229960001269 glycine hydrochloride Drugs 0.000 abstract 1
- 239000008363 phosphate buffer Substances 0.000 abstract 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002146155 | 2002-05-21 | ||
PCT/JP2003/006349 WO2003097083A1 (fr) | 2002-05-21 | 2003-05-21 | Compositions medicinales contenant de la ghreline |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0306685A true BR0306685A (pt) | 2005-04-26 |
Family
ID=29545111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0306685-1A BR0306685A (pt) | 2002-05-21 | 2003-05-21 | Composição farmacêutica contendo grelina |
Country Status (11)
Country | Link |
---|---|
US (3) | US20060166871A1 (pt) |
EP (1) | EP1506786B1 (pt) |
JP (1) | JP5000848B2 (pt) |
KR (1) | KR20050012224A (pt) |
CN (1) | CN100411683C (pt) |
AU (1) | AU2003235401B2 (pt) |
BR (1) | BR0306685A (pt) |
CA (1) | CA2471879C (pt) |
ES (1) | ES2615484T3 (pt) |
IL (2) | IL162796A0 (pt) |
WO (1) | WO2003097083A1 (pt) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE552031T1 (de) | 2001-12-18 | 2012-04-15 | Alize Pharma Sas | Pharmazeutische zusammensetzungen enthaltend nicht-acyliertes ghrelin zur behandlung von insulinresistenz |
US7666833B2 (en) | 2001-12-18 | 2010-02-23 | Alizé Pharma SAS | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
IL162796A0 (en) | 2002-05-21 | 2005-11-20 | Kenji Kangawa | Medicinal compositions containing ghrelin |
CA2496687A1 (en) * | 2002-09-18 | 2004-04-01 | Centre Hospitalier De L'universite De Montreal (Chum) | Ghrh analogues |
EP1694355A4 (en) * | 2003-10-24 | 2009-07-29 | Alize Pharma Sas | USE OF GHRELINE AND NON-ACYLATED GHRELINE COMPOSITIONS IN INSULIN RELATED DISEASES |
CN1321131C (zh) * | 2003-12-26 | 2007-06-13 | 李宁 | 猪Ghrelin衍生物及其编码基因与应用 |
US20080269116A1 (en) * | 2004-05-11 | 2008-10-30 | Taub Dennis D | Methods of Inhibiting Proinflammatory Cytokine Expression Using Ghrelin |
CA2576915A1 (en) * | 2004-08-18 | 2006-03-02 | Elixir Pharmaceuticals, Inc. | Growth-hormone secretagogues |
CN101022822B (zh) * | 2004-08-24 | 2012-06-27 | 第一三共株式会社 | 生理学活性肽的液体制剂 |
WO2006053383A1 (en) * | 2004-11-22 | 2006-05-26 | Anadis Ltd | Bioactive compositions |
EP1875928A4 (en) * | 2005-04-15 | 2012-03-21 | Univ Shinshu | NEW METHOD FOR THE USE OF TRIACETIN AND TOOLS FOR DIAGNOSTIC ULTRASOUND EXAMINATION |
JP5033798B2 (ja) * | 2005-07-02 | 2012-09-26 | アレコー・リミテッド | タンパク質を含む安定水系 |
AU2006316100B2 (en) * | 2005-11-21 | 2011-12-01 | Daiichi Sankyo Company, Limited | Therapeutic agent for skin or skin repair-promoting agent comprising ghrelin, derivative thereof or substance capable of acting on GHS-R1a as active ingredient |
WO2007088681A1 (ja) | 2006-01-31 | 2007-08-09 | National University Corporation Hokkaido University | グレリン産生促進剤 |
US20100227806A1 (en) * | 2006-03-10 | 2010-09-09 | Tulipano Giovanni | Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment |
KR101201055B1 (ko) * | 2006-03-13 | 2012-11-15 | 리아트 민쯔 | 악액질 및/또는 식욕감퇴 및/또는 식욕감퇴-악액질 및/또는영양장애 및/또는 지방이영양증 및/또는 근육 쇠약 및/또는 식욕-자극의 치료를 위한 그렐린 스플라이스 변이체의 용도 |
US7763707B2 (en) | 2006-03-13 | 2010-07-27 | Liat Mintz | Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation |
US8299022B2 (en) * | 2006-09-27 | 2012-10-30 | Ipsen Pharma S.A.S. | Analogs of ghrelin substituted at the N-terminal |
GB0700523D0 (en) * | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
CN101678084B (zh) | 2007-05-31 | 2015-01-21 | 阿利兹药物股份有限公司 | 未酰基化的生长素释放肽作为治疗代谢紊乱中的治疗剂 |
US8318664B2 (en) | 2007-05-31 | 2012-11-27 | Alize Pharma Sas | Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity |
WO2009033773A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use endothelin 2, alone or combined with a nonapeptide, a peptide as a therapeutic agent |
CN102066401A (zh) | 2008-05-01 | 2011-05-18 | 艾瑞克有限公司 | 蛋白质制品 |
US8476408B2 (en) | 2008-06-13 | 2013-07-02 | Alize Pharma Sas | Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease |
EP2328607A1 (en) | 2008-07-16 | 2011-06-08 | Arecor Limited | Stable formulation of a therapeutic protein |
CA2774999A1 (en) | 2009-09-30 | 2011-04-07 | President And Fellows Of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products |
JP2015505300A (ja) | 2011-11-23 | 2015-02-19 | アムジエン・インコーポレーテツド | インターフェロンγに対する抗体を使用した治療方法 |
JP6031121B2 (ja) | 2011-12-15 | 2016-11-24 | アリゼ ファーマ エスアーエス | 非アシル化グレリンを使用したグレリンレベル及びグレリン/非アシル化グレリン比の調節 |
US9657062B2 (en) | 2012-02-03 | 2017-05-23 | Zealand Pharma A/S | Ghrelin analogues |
FR2987268B1 (fr) * | 2012-02-28 | 2014-07-11 | Ammtek | Formulations liquides de sulfamides hypoglycemiants |
WO2015017123A1 (en) | 2013-07-16 | 2015-02-05 | Liat Mintz | Ghrelin splice variant for treating neuronal damage,neurodegenerative disease, parkinsons disease, alzheimers disease, and/or depression |
US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
EP3191111A4 (en) | 2014-09-09 | 2018-06-13 | The Feinstein Institute for Medical Research | Treatment of radiation injury using ghrelin |
CA2962630C (en) * | 2014-09-27 | 2023-02-21 | Sumitomo Dainippon Pharma Co., Ltd. | Pharmaceutical composition for injection |
JP6694216B2 (ja) | 2015-10-14 | 2020-05-13 | 学校法人 久留米大学 | グレリンを有効成分として含有するレット症候群(rtt)の予防・治療剤 |
US20170121385A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
JP2018169273A (ja) * | 2017-03-29 | 2018-11-01 | 東ソー株式会社 | ペプチドの吸着抑制剤 |
CA3103986A1 (en) * | 2018-07-03 | 2020-01-09 | Fennec Pharmaceuticals, Inc. | Formulations of anhydrous sodium thiosulfate |
CA3139341A1 (en) * | 2019-05-07 | 2020-11-12 | Frontier Biotechnologies Inc. | Stable albuvirtide compositions |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0651637B2 (ja) * | 1985-03-28 | 1994-07-06 | エーザイ株式会社 | ペプタイドの吸着防止組成物 |
JPS62238298A (ja) * | 1986-04-08 | 1987-10-19 | Sanraku Inc | 新規アントラサイクリン抗生物質dcp−1及び2 |
JPH0669956B2 (ja) * | 1988-09-30 | 1994-09-07 | 旭化成工業株式会社 | ポリペプタイド類の吸着防止剤 |
DE4126983A1 (de) * | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke |
SE9300105D0 (sv) | 1993-01-15 | 1993-01-15 | Kabi Pharmacia Ab | Stable protein solution |
US5482931A (en) * | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
DE4340781C3 (de) | 1993-11-30 | 2000-01-27 | Novartis Ag | Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung |
JP2758154B2 (ja) | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
US5843903A (en) * | 1995-11-27 | 1998-12-01 | The Administrators Of The Tulane Educational Fund | Targeted cytotoxic anthracycline analogs |
US5780431A (en) | 1996-09-20 | 1998-07-14 | Neurobiological Technologies, Inc. | Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form |
US5998381A (en) * | 1996-12-06 | 1999-12-07 | Ophidian Pharmaceuticals, Inc. | Compounds that bind bacterial pili |
CA2343268A1 (en) | 1998-09-17 | 2000-03-23 | Eli Lilly And Company | Protein formulations |
ATE449174T1 (de) * | 1999-07-23 | 2009-12-15 | Kenji Kangawa | Neue peptide |
WO2001087322A2 (en) | 2000-05-17 | 2001-11-22 | Bionebraska, Inc. | Peptide pharmaceutical formulations |
WO2001087335A2 (en) * | 2000-05-17 | 2001-11-22 | Eli Lilly And Company | Method for selectively inhibiting ghrelin action |
IL147731A0 (en) | 2000-05-19 | 2002-08-14 | Bionebraska Inc | Peptide pharmaceutical formulations |
US6967237B2 (en) * | 2000-05-30 | 2005-11-22 | Merck & Co., Inc. | Ghrelin analogs |
DK1412384T3 (da) | 2001-06-28 | 2008-04-28 | Novo Nordisk As | Stabil formulering af modificeret GLP-1 |
CN100491395C (zh) * | 2002-04-11 | 2009-05-27 | 阿斯比奥制药株式会社 | 修饰肽的制造方法 |
IL162796A0 (en) | 2002-05-21 | 2005-11-20 | Kenji Kangawa | Medicinal compositions containing ghrelin |
-
2003
- 2003-05-21 IL IL16279603A patent/IL162796A0/xx active IP Right Grant
- 2003-05-21 BR BR0306685-1A patent/BR0306685A/pt not_active IP Right Cessation
- 2003-05-21 EP EP03752939.3A patent/EP1506786B1/en not_active Expired - Lifetime
- 2003-05-21 AU AU2003235401A patent/AU2003235401B2/en not_active Expired
- 2003-05-21 JP JP2004505079A patent/JP5000848B2/ja not_active Expired - Lifetime
- 2003-05-21 US US10/500,561 patent/US20060166871A1/en not_active Abandoned
- 2003-05-21 CA CA2471879A patent/CA2471879C/en not_active Expired - Lifetime
- 2003-05-21 ES ES03752939.3T patent/ES2615484T3/es not_active Expired - Lifetime
- 2003-05-21 KR KR10-2004-7010362A patent/KR20050012224A/ko not_active Application Discontinuation
- 2003-05-21 WO PCT/JP2003/006349 patent/WO2003097083A1/ja active Application Filing
- 2003-05-21 CN CNB038028301A patent/CN100411683C/zh not_active Expired - Lifetime
-
2004
- 2004-06-30 IL IL162796A patent/IL162796A/en unknown
-
2007
- 2007-07-25 US US11/878,532 patent/US8440628B2/en not_active Expired - Lifetime
-
2012
- 2012-03-06 US US13/413,581 patent/US8518893B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20060166871A1 (en) | 2006-07-27 |
CN1622822A (zh) | 2005-06-01 |
CA2471879C (en) | 2014-02-25 |
EP1506786A1 (en) | 2005-02-16 |
CN100411683C (zh) | 2008-08-20 |
KR20050012224A (ko) | 2005-01-31 |
US20080081787A1 (en) | 2008-04-03 |
US20120264691A1 (en) | 2012-10-18 |
JP5000848B2 (ja) | 2012-08-15 |
IL162796A (en) | 2011-01-31 |
EP1506786A4 (en) | 2009-07-29 |
CA2471879A1 (en) | 2003-11-27 |
AU2003235401B2 (en) | 2008-09-25 |
JPWO2003097083A1 (ja) | 2005-10-06 |
EP1506786B1 (en) | 2016-11-23 |
IL162796A0 (en) | 2005-11-20 |
AU2003235401A1 (en) | 2003-12-02 |
US8518893B2 (en) | 2013-08-27 |
US8440628B2 (en) | 2013-05-14 |
WO2003097083A1 (fr) | 2003-11-27 |
ES2615484T3 (es) | 2017-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0306685A (pt) | Composição farmacêutica contendo grelina | |
BR0300826A (pt) | Formulação antitumor com base em paclitaxel melhorada | |
Zahlten et al. | The influence of ammonium and calcium ions on gluconeogenesis in isolated rat hepatocytes and their response to glucagon and epinephrine | |
US5026825A (en) | Intranasal calcitonin formulations | |
CA2672902A1 (en) | Formulations | |
TR200801968T2 (tr) | HFSH sulu formülasyon. | |
EA200700389A1 (ru) | Стабильный при хранении инфузионный раствор дигидроптеридинонов | |
BR0014486A (pt) | Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado | |
DK1044015T3 (da) | Formuleringer med amylinagonistpeptider og insulin | |
AR040529A1 (es) | Formulaciones de hgh en alta concentracion que contienen 1,2-propilenglicol | |
EA200601874A1 (ru) | Жидкий состав гормона роста | |
ES2224917T1 (es) | Composiciones farmaceuticas de agente fibrinolitico. | |
CA2234724A1 (en) | Stable pharmaceutical forms of administration containing parathyroid hormone | |
DE60301878D1 (de) | Pharmazeutische zusammensetzung enthaltend ein alpha-ketoalkansäureester oder -amid und milchsäure oder ein milchsäuresalz | |
ES2229931A1 (es) | Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos. | |
ES2283446T3 (es) | Composicion de gel basada en alcohol para el tratamiento del hipogonadismo por administracion transescrotal. | |
RU2004133349A (ru) | Жидкий препарат, содержащий производное кампототецина, и фармацевтическая композиция, получаемая путем лиофилизации препарата | |
BR9803730A (pt) | Preparados farmacêuticos de cilansetron estabilizados contra a racemização. | |
DK1153615T3 (da) | Farmaceutisk formulering til intravenøs eller intramuskulær octreotid-indgivelse | |
ATE359059T1 (de) | Zubereitungen zur intranasalen applikation ausgewählter, von aminosäuren abgeleiteter cgrp- antagonisten | |
MXPA05008860A (es) | Composiciones farmaceuticas estabilizadas de safingol y metodos para utilizar las mismas. | |
DE60034149D1 (de) | Hydrophobe aminosäuren enthaltende trockene zusammensetzung | |
ES2245252B1 (es) | Solucion acuosa de risperidona para administracion oral. | |
DE60141632D1 (de) | Zusammensetzung zur stabilisierung von fettlöslichen vitaminen in wässeriger lösung | |
AR121364A1 (es) | Formulaciones farmacéuticas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: KENJI KANGAWA (JP) , DAIICHI ASUBIO PHARMA CO., LT Free format text: ALTERADO DE: DAIICHI SUNTORY PHARMA CO., LTD. |
|
B25G | Requested change of headquarter approved |
Owner name: KENJI KANGAWA (JP) , DAIICHI ASUBIO PHARMA CO., LT Free format text: ALTERADA A SEDE DO TITULAR CONFORME REQUERIDA ATRAVES DA PETICAO NO 020050150101/RJ DE 20/12/2005. |
|
B25D | Requested change of name of applicant approved |
Owner name: KENJI KANGAWA (JP) , ASUBIO PHARMA CO., LTD. (JP) Free format text: ALTERADO DE: DAIICHI ASUBIO PHARMA CO., LTD. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25C | Requirement related to requested transfer of rights |
Owner name: KENJI KANGAWA (JP) , ASUBIO PHARMA CO., LTD. (JP) Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 020100090868/RJ DE 28/09/2010, APRESENTE O DOCUMENTO DE FUSAO COM A DEVIDA LEGALIZACAO CONSULAR. |
|
B25A | Requested transfer of rights approved |
Owner name: KENJI KANGAWA (JP) , DAIICHI SANKYO COMPANY, LIMIT Free format text: TRANSFERIDO POR FUSAO DE: ASUBIO PHARMA CO., LTD. |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 18A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2622 DE 06/04/2021. |